tiprankstipranks
NLS Pharmaceutics announces patent grant for Mazindol
The Fly

NLS Pharmaceutics announces patent grant for Mazindol

NLS Pharmaceutics announced that the Patents Registry, Intellectual Property Department of The Government of the Hong Kong Special Administrative Region has granted approval for Patent Application 42022055879.5, which covers Mazindol ER as a method of treatment for ADHD. This patent is expected to expire no earlier than 2037.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NLSP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles